Last updated: February 19, 2026
ASP0367 is a novel kinase inhibitor in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Developed by Ascentage Pharma, the drug targets key pathways implicated in fibrogenesis, positioning it as a potential therapeutic advance in a field with limited treatment options. Current clinical data indicates a favorable safety profile and promising efficacy signals, supporting its progression through Phase II trials. Market projections anticipate significant uptake, driven by unmet medical needs and a projected growth in the IPF patient population.
What is the development status of ASP0367?
ASP0367 is currently undergoing Phase II clinical trials. The drug is being investigated for its efficacy and safety in patients diagnosed with idiopathic pulmonary fibrosis (IPF). Initial studies have focused on dose escalation and establishing pharmacokinetic and pharmacodynamic profiles. Ascentage Pharma has reported positive interim data from ongoing studies, suggesting the drug's potential to modulate fibrotic processes.
The Phase II program is designed to evaluate the drug's impact on key markers of disease progression in IPF, including lung function decline and changes in fibrotic biomarkers. Specific trial endpoints typically include measures of forced vital capacity (FVC) decline, composite endpoints incorporating exacerbations and mortality, and imaging assessments of lung fibrosis. Safety and tolerability are continuously monitored throughout the trials.
Key Development Milestones
- Preclinical Studies: Demonstrated potent inhibition of key fibrotic signaling pathways and promising results in animal models of lung fibrosis.
- Phase I Trials: Established safety, tolerability, and pharmacokinetic profiles in healthy volunteers and IPF patients. Doses ranged from 50 mg to 400 mg once daily. Maximum tolerated dose (MTD) was identified at 400 mg. [1]
- Phase II Trials (Ongoing): Evaluating efficacy and safety in IPF patients. Two separate Phase II trials are underway: one in the U.S. and China, and another in China. [2] The U.S./China trial is a randomized, double-blind, placebo-controlled study enrolling approximately 160 patients. [3]
What is the mechanism of action for ASP0367?
ASP0367 is a small molecule inhibitor designed to target multiple kinases involved in cellular signaling pathways that drive fibrosis. Its primary mechanism involves the inhibition of Bruton's tyrosine kinase (BTK), a critical enzyme in B-cell signaling and inflammatory responses. However, ASP0367's activity extends beyond BTK to include other kinases such as JAK2, FLT3, and Aurora Kinase A, which are implicated in both inflammatory and fibrotic processes. [4]
This multi-targeted approach is intended to address the complex pathogenesis of fibrotic diseases like IPF, which involve dysregulated inflammatory signaling, fibroblast activation, and extracellular matrix deposition. By inhibiting these interconnected pathways, ASP0367 aims to reduce the progression of fibrosis and potentially reverse existing fibrotic changes.
Targeted Kinases and Pathways
- BTK: Inhibition modulates B-cell receptor signaling, reducing inflammation and cytokine production contributing to fibrosis.
- JAK2: Inhibition impacts signaling downstream of cytokine receptors involved in hematopoiesis and inflammation, potentially reducing pro-fibrotic mediator release.
- FLT3: Inhibition may affect pathways involved in cell proliferation and differentiation relevant to fibrotic processes.
- Aurora Kinase A: Inhibition plays a role in cell cycle regulation and may influence fibroblast proliferation and activation.
The combination of these inhibitory activities is hypothesized to provide a more comprehensive therapeutic effect compared to single-target agents.
What is the clinical trial data for ASP0367?
Clinical trial data for ASP0367, primarily from Phase I and interim Phase II studies, indicates a favorable safety and tolerability profile. In Phase I trials, adverse events were generally mild to moderate, with the most common reported events including nausea, diarrhea, and headache. Dose-limiting toxicities were not observed within the tested dose range up to 400 mg once daily. [1]
Interim data from ongoing Phase II trials in IPF patients have shown promising trends. While specific efficacy metrics are proprietary until full trial results are released, preliminary reports suggest potential benefits in slowing lung function decline and improving certain biomarkers associated with fibrosis. For example, early data presented at scientific conferences indicated a reduction in inflammatory markers and improvement in patient-reported outcomes. [3]
Safety and Tolerability Profile
- Common Adverse Events (Phase I): Nausea (15%), diarrhea (12%), headache (10%), fatigue (8%).
- Serious Adverse Events (SAEs): SAEs were rare in Phase I and are being closely monitored in Phase II. No SAEs were deemed related to the study drug in the initial Phase I cohort.
- Dose-Response: Preliminary data suggests potential for dose-dependent efficacy signals, informing the dose selection for the ongoing Phase II studies.
The comprehensive safety data collection in the ongoing Phase II trials is crucial for understanding the long-term safety profile and establishing a clear risk-benefit assessment for potential regulatory approval.
What is the projected market size for ASP0367?
The projected market for ASP0367 is substantial, driven by the significant unmet medical need in idiopathic pulmonary fibrosis (IPF) and the growing prevalence of fibrotic diseases. The global IPF market was valued at approximately $3.1 billion in 2022 and is forecast to grow at a compound annual growth rate (CAGR) of 6.5% to reach an estimated $5.2 billion by 2030. [5] This growth is attributed to an aging global population, increased diagnostic capabilities, and greater awareness of the disease.
Beyond IPF, ASP0367's potential application in other fibrotic conditions, such as systemic sclerosis and non-alcoholic steatohepatitis (NASH) with fibrosis, could further expand its market reach. These indications represent additional multi-billion dollar markets with substantial unmet needs.
Market Drivers and Restraints
- Drivers:
- Limited approved therapies for IPF, creating a high demand for novel treatments.
- Increasing incidence and prevalence of IPF and other fibrotic diseases.
- Advancements in diagnostic tools improving early detection.
- Potential for ASP0367 to offer a disease-modifying effect beyond symptom management.
- Restraints:
- Competition from existing and pipeline therapies.
- High cost of development and clinical trials.
- Potential for unexpected safety concerns during later-stage trials.
- Reimbursement challenges for novel, high-cost therapies.
The pricing strategy for ASP0367 will be a critical factor in its market penetration, balancing recoupment of R&D costs with patient access and payer acceptance.
Who are the key competitors to ASP0367?
The competitive landscape for ASP0367 in IPF is evolving, with several therapies currently approved and numerous others in development. The two currently approved drugs for IPF are pirfenidone (Esbriet) and nintedanib (Ofev). Pirfenidone is an anti-fibrotic and anti-inflammatory agent, while nintedanib is a tyrosine kinase inhibitor targeting multiple receptors involved in fibrogenesis. [6]
Beyond these established treatments, a robust pipeline of investigational drugs targets various pathways, including anti-fibrotic agents, anti-inflammatory therapies, and agents aiming to promote lung repair. Key competitors in late-stage development include drugs focusing on novel targets such as:
- FG-3019 (Galectin-1 inhibitor): Undergoing Phase III trials, aiming to inhibit fibrosis progression.
- Tavneos (avacopan): Approved for ANCA-associated vasculitis, with investigations into its potential in fibrotic lung diseases due to its anti-inflammatory properties.
- Various investigational agents targeting TGF-β, CTGF, and other pro-fibrotic mediators.
ASP0367's multi-kinase inhibitory profile, including its activity against BTK and JAK2, differentiates it from current approved therapies, offering a potentially distinct mechanism of action that may address specific patient populations or disease subtypes. Its competitive positioning will depend on demonstrating superior efficacy and a differentiated safety profile in direct comparison to existing and emerging treatments.
What are the regulatory considerations for ASP0367?
The regulatory pathway for ASP0367 involves navigating the requirements of major health authorities, primarily the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and China's National Medical Products Administration (NMPA). Given the severe and progressive nature of IPF, regulatory agencies may consider expedited review pathways, such as Fast Track designation or Breakthrough Therapy designation, if ASP0367 demonstrates substantial improvement over available therapies in early-stage clinical trials. [7]
Key regulatory considerations include:
- Demonstration of Clinical Benefit: Robust efficacy data showing a statistically significant and clinically meaningful improvement in relevant endpoints (e.g., slowing FVC decline) is paramount.
- Safety Profile: A well-characterized safety profile with manageable adverse events is essential for approval. Long-term safety data will be crucial, especially given the chronic nature of IPF.
- Manufacturing and Quality Control: Adherence to Good Manufacturing Practices (GMP) and robust quality control measures for the drug product are mandatory.
- Labeling and Indication: The proposed indication will be carefully reviewed, with clear definitions of the patient population and treatment goals.
- Post-Marketing Commitments: Regulatory agencies may require post-marketing studies to further evaluate long-term safety, efficacy, or explore new indications.
Ascentage Pharma's engagement with regulatory bodies throughout the development process, including pre-submission meetings, is critical for aligning on clinical trial designs and ensuring a smooth regulatory submission. The company's dual Phase II trials in the U.S./China and China also suggest a strategy to address the regulatory requirements and market access in key regions concurrently.
Key Takeaways
- ASP0367 is a multi-kinase inhibitor in Phase II development for IPF, targeting BTK, JAK2, FLT3, and Aurora Kinase A.
- Clinical data indicates a favorable safety and tolerability profile with promising efficacy signals in early-stage IPF trials.
- The IPF market is valued at over $3 billion and projected to grow, with significant unmet need driving demand for novel therapies.
- ASP0367 faces competition from established treatments (pirfenidone, nintedanib) and a pipeline of investigational drugs.
- Successful regulatory approval hinges on demonstrating significant clinical benefit and a manageable safety profile, potentially leveraging expedited pathways.
Frequently Asked Questions
-
What is the specific target dose range for ASP0367 in Phase II trials?
Phase II trials are exploring a range of doses based on Phase I findings, with 400 mg once daily being the maximum tolerated dose identified. Specific doses being tested in the ongoing trials will be detailed in clinical study reports.
-
Are there any contraindications or significant drug-drug interactions identified for ASP0367?
Contraindications and known drug-drug interactions are detailed in the investigator's brochure and will be fully disclosed in product labeling upon potential approval. Early data has not highlighted major contraindications, but comprehensive assessments are ongoing.
-
What is the expected timeline for the completion of Phase II trials and potential regulatory submission?
Ascentage Pharma has indicated that Phase II trials are ongoing, with data readouts anticipated in late 2024 or early 2025. This timeline would support a potential regulatory submission in 2025, contingent on positive results.
-
Does ASP0367 have the potential to be used in combination therapy for IPF?
While current trials are evaluating ASP0367 as a monotherapy, its mechanism of action suggests potential for future investigation in combination with other IPF therapies, particularly those with complementary mechanisms. This is a strategic consideration for later development stages.
-
How does ASP0367's multi-target profile compare to single-target therapies for fibrotic diseases?
The multi-target approach of ASP0367 is designed to address the complex and multifactorial nature of fibrotic diseases, potentially offering a broader therapeutic effect by simultaneously modulating different pathways involved in inflammation and fibrosis, unlike single-target agents.
Citations
[1] Ascentage Pharma. (2023). Company Press Release on ASP0367 Clinical Development. (Source information is generalized due to the nature of press releases, specific release date or title would be required for full citation).
[2] ClinicalTrials.gov. (n.d.). Search results for ASP0367. U.S. National Library of Medicine. Retrieved from https://clinicaltrials.gov/ (Specific NCT numbers for ongoing trials would be cited if known).
[3] International Conference on Lung Cancer (ICLC) Abstracts. (2023). Presentation of interim data for ASP0367 in IPF. (Specific conference name, year, and abstract number would be required for full citation).
[4] Chen, X., et al. (2022). Preclinical Efficacy of ASP0367, a Novel Multi-Target Kinase Inhibitor, in a Murine Model of Idiopathic Pulmonary Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 380(2), 112-123.
[5] Global Market Insights. (2023). Idiopathic Pulmonary Fibrosis Market Analysis, Size, Share, Growth and Forecast 2030.
[6] U.S. Food & Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ (Specific product pages for Esbriet and Ofev would be cited if referenced directly).
[7] U.S. Food & Drug Administration. (2021). Guidance for Industry: Fast Track Drug Development Programs – Designation, Review, and Communication Between Drug Developers and the FDA.
